News

Covidien’ subsidiary, Mallinckrodt is voluntarily recalling one lot of Mallinckrodt Sodium Chromate Cr-51 Injection (lot #370-9004), as a result of routine post-market testing in which the product was

Revance Therapeutics’ RT001, a topical botulinum toxin type A, under investigation for the treatment of crow’s feet wrinkles, has demonstrated efficacy and safety in a US phase 2b

“Millennium has a strong focus on applications with expert technical sales and support. They are a natural fit for BioTek as we grow in Australasia,” noted Dominic Herring,

Bioheart has announced successful completion of series D financing, that commenced on October 1, 2008, and through July 7, 2009. Bioheart has raised an amount of $2.8 million

Stem Cell has issued two patents in India, Indian Patent No. 229684 entitled – Combined Regulation of Neural Cell Production, and Indian Patent No. 229924 entitled – A

Allon has released top-line results from phase-IIa clinical trial showing that the neuroprotective drug candidate, davunetide intranasal (AL-108), has a positive impact on the ability of schizophrenia patients.

Schering-Plough has received marketing approval for Remeron/Reflex (mirtazapine) 15mg tablets, for the treatment of major depressive disorder. The product was developed jointly with Meiji Seika Kabushiki Kaisha. Schering-Plough

Dor BioPharma has received a European patent for its Lipid Polymer Micelle (LPM) technology, for the improved oral delivery of drugs. The issued European patent, EP 1460992, entitled

Bayer Schering Pharma has submitted a New Drug Application (NDA) to the FDA for a new estradiol-based oral contraceptive (estradiol valerate/dienogest). It seeks approval for the indications oral